Success! The link has been copied to your clipboard.
Fresenius Medical Care North America Comments on Voter’s Overwhelming Rejection of Proposition 23 in California
News Release | Published: 11.04.2020
Patient Care
We deliver high-quality care with innovation and empathy.
We deliver high-quality care with innovation and empathy.
PRACTICE SUPPORT
Products
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Insights
Our Company
More
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Success! The link has been copied to your clipboard.
News Release | Published: 11.04.2020
WALTHAM, Mass. – Nov. 4, 2020 - Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, today released the following statement in response to the overwhelming rejection of the ballot initiative Proposition 23 in California.
“It’s good news for patients that California voters have sided with a wide coalition of healthcare providers rejecting Proposition 23,” said Bill Valle, CEO of Fresenius Medical Care North America. “This result is in the patients' best interest as it safeguards access to dialysis in California by avoiding redundant and unnecessary requirements. The overwhelming vote against Proposition 23 allows us to maintain our focus on providing the highest quality care possible for our patients needing life-sustaining treatment.”
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.
© 2006-2023 Fresenius Medical Care. All Rights Reserved.